AU Patent

AU2018229508B2 — Pharmaceutical cream compositions comprising oxymetazoline

Assigned to EPI Health LLC · Expires 2020-06-25 · 6y expired

What this patent protects

PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE Abstract: Overall Makeup Moist Dry Irritate App Over Absorp Ease I Trial 20 Elegant IN Trial 11 Oily 1@ Trial 2 Tack Se Trial 36 Smell Color App FIG.1 0 2 4 6 8 Embodiments relating to cream formulati…

USPTO Abstract

PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE Abstract: Overall Makeup Moist Dry Irritate App Over Absorp Ease I Trial 20 Elegant IN Trial 11 Oily 1@ Trial 2 Tack Se Trial 36 Smell Color App FIG.1 0 2 4 6 8 Embodiments relating to cream formulations as well as oxymetazoline creams and methods for treating rosacea and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith; other inflammatory conditions of the skin including, but not limited to, keratosis pilaris, lupus miliaris dissemniatus faciei, eczema, dermatitis, such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, statis dermatitis, neurodermatitis, lichen simplex chronicus, xerosis and xerotic dermatitis, dyshidrosis and dyshidrotic dermatitis, asteototic dermatitis or other conditions characterized by sensitive skin or a disturbance of the epidermal barrier; disorders characterized by rough, dry, cracked or fissured skin, disorders characterized by hyperkeratotic skin such as keratodermas and ichthyosisis and ichthyosiform dermatoses; disorders of hair follicles and sebaceous glands, such as acne, perioral dermatitis, and pseudofolliculitis barbae; disorders of sweat glands, such as miliaria, including, but not limited to, miliaria crystallina, miliaria rubra, miliaria profunda, miliaria pustulosa; sunburn, chronic actinic damage, poikiloderma, radiation dermatitis, actinic purpura ("solar purpura"); other inflammatory dermatoses, reactions and conditions of the skin, including, but not limited to, psoriasis, drug eruptions, erythema multiforme, erythema nodosum, and granuloma annulare; diseases and conditions characterized by bleeding or bruising such as petechiae, ecchymosis, purpura and the like including any accumulation of blood in the skin due to vascular extravasation, irrespective of size or cause, bleeding or bruising due to any skin injury which may include any trauma including surgical or procedural trauma; infection, inflammatory dermatoses or inflammation due to any cause using such creams are described herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018229508B2
Jurisdiction
AU
Classification
Expires
2020-06-25
Drug substance claim
No
Drug product claim
No
Assignee
EPI Health LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.